Japanese Oil and Gas Stock News

Markets are being pulled in different directions by higher oil prices, sticky inflation signals, and shifting rate expectations across the US, Europe, and Asia. In this kind of cross-current, many investors are looking for solid footing rather than the next hot story. That is where the Low-Risk Leaders screener comes in, focusing on companies with resilient balance sheets and lower model risk scores that can help anchor a portfolio while maintaining a focus on attractive returns. In this...

If you are wondering whether SoftBank Group's rapid swings in sentiment point to a bargain or a bubble, this article focuses squarely on what the current share price might really represent. The stock last closed at ¥5,424, with returns of 3.0% over 7 days, 48.7% over 30 days, 17.5% year to date, 193.3% over 1 year and 143.4% over 5 years. That puts recent moves front and center in any valuation conversation. Those price shifts sit against a backdrop of ongoing headlines about SoftBank...

A lackluster earnings announcement from Hokkaido Electric Power Company, Incorporated ( TSE:9509 ) last week didn't...

Heiwa Real Estate Co., Ltd. ( TSE:8803 ) shareholders will have a reason to smile today, with the analysts making...

In April 2026, Kyocera Corporation announced a share repurchase program of up to 156,544,000 shares for ¥250,000,000,000, alongside full-year results showing higher sales and net income compared with the prior year. Together with a board review of its Articles of Incorporation and dividend policy, these moves highlight Kyocera’s focus on capital flexibility and shareholder returns while advancing ceramic substrates for AI-focused semiconductor packaging. We’ll now examine how Kyocera’s...

TOTO LTD. reported full-year results for the period ended March 31, 2026, with sales of ¥737,441 million and net income of ¥40,257 million, and its board met on April 30, 2026 to consider a year-end dividend with a March 31, 2026 record date. A key highlight was the strong contribution from TOTO’s semiconductor ceramics business, which helped lift earnings per share from continuing operations to about ¥243 on both a basic and diluted basis. We’ll now explore how this earnings performance,...

Socionext Inc. recently reported full-year results for the period ended March 31, 2026, with higher sales of ¥200,834 million but lower net income of ¥8,733 million year on year, reaffirmed an annual dividend of ¥25.00 per share, and issued earnings guidance for fiscal 2027. Amid this mix of revenue growth, profit compression, and an unchanged dividend, Socionext’s forward guidance for ¥215,000 million in net sales and basic EPS of ¥57.05 offers fresh context for how management is...

Shimano Inc. has already reported first-quarter 2026 results, with sales rising to ¥117,644 million and net income increasing to ¥12,814 million, and its board considering the disposal of treasury shares as restricted stock remuneration. The company also raised its earnings guidance for 2026, with the higher net income outlook driven partly by gains on sales of cross-shareholdings booked as extraordinary income. We will now examine how Shimano’s stronger first-quarter earnings and upgraded...

Sojitz Corporation recently reported full-year results for the 12 months to March 31, 2026, with revenue rising to ¥2,757.35 billion while net income eased to ¥103.61 billion, alongside slightly lower basic and diluted earnings per share from continuing operations. On the same day, the board met to discuss year-end and interim cash dividends, signaling continued attention to shareholder returns despite softer profitability. With earnings growth in revenue but a dip in net income, we’ll now...

Board decision and why it matters for Sanrio stock Sanrio Company (TSE:8136) has attracted investor attention after its board decided to postpone announcing financial results for the year ended March 2026 and to set up a Special Investigation Committee. See our latest analysis for Sanrio Company. The board announcement comes after a period of weaker momentum in the share price, with a 7 day share price return of 6.35% and a 30 day share price return of 8.31%. The 1 year total shareholder...

Dassault Systèmes and OMRON recently announced a partnership that links Dassault’s 3D virtual twin technology with OMRON’s Sysmac industrial automation platform, enabling manufacturers to design, simulate, and validate production systems in a unified virtual-physical environment. A distinctive aspect of this collaboration is the continuous feedback loop between real-time sensor and robot data and the virtual twin, which can improve system optimization, safety testing, and maintenance...

Kyowa Kirin and Kura Oncology recently dosed the first patient in a Japanese Phase 2 registrational trial of ziftomenib, an oral menin inhibitor, for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia, following its prior approval in the US as KOMZIFTI. This trial targets a genetic subtype representing around 30% of AML cases in Japan and could support Kyowa Kirin’s planned regulatory filing, while also extending the clinical footprint of a therapy already in use...

As global markets navigate through a period of heightened geopolitical tensions and economic uncertainties, Asian markets have shown resilience with stable performances and strategic policy adjustments. In this environment, identifying stocks that are potentially undervalued can be an effective strategy for investors looking to capitalize on market inefficiencies.

Oriental Land Co., Ltd. has already reported its full-year results for the year ended March 31, 2026, showing higher sales but slightly lower net income than the prior year, while the board proposed raising the year-end dividend to ¥8.00 per share from ¥7.00 and outlined further dividend plans. The company also issued detailed earnings and dividend guidance through the fiscal year ending March 31, 2027, giving investors clearer visibility on expected sales, profit and cash returns to...

Investors in Japan Airlines Co., Ltd. ( TSE:9201 ) had a good week, as its shares rose 3.4% to close at JP¥2,527...

AGC stock in focus after expanded biologics agreement AGC (TSE:5201) has come into focus after AGC Biologics expanded its manufacturing agreement with Novelty Nobility and advanced plans for a new large scale biologics facility in Yokohama, Japan. The latest agreement extends work on a bispecific antibody drug candidate, progressing from successful cell line development in Copenhagen to process development and GMP manufacturing in Chiba, supported by AGC Biologics’ integrated global...

Earnings event puts fresh focus on Keyence stock Keyence (TSE:6861) has drawn fresh attention after reporting full year 2026 results, with sales of ¥1,169,289 million and net income of ¥445,185 million compared to the prior year. See our latest analysis for Keyence. The earnings announcement and board updates have coincided with a sharp shift in sentiment, with a 1 day share price return of 7.24% and 30 day share price return of 32.44%. The 5 year total shareholder return of 47.62% points to...

What recent performance says about Seven & i Holdings With no single headline event driving trading, Seven & i Holdings (TSE:3382) has drawn attention after a 2.5% move over the past day, contrasting with weaker returns over the past month. See our latest analysis for Seven & i Holdings. The latest 2.5% 1 day share price gain to ¥1,918.5 comes after a weaker patch, with a 30 day share price return of a 12.0% decline and a 1 year total shareholder return of an 11.66% decline, indicating...

In April 2026, Babcock Power Services Inc., Riley Power Inc., and IHI Corporation signed a collaboration agreement to convert existing power plant boilers worldwide to low-carbon fuels, especially ammonia, drawing on IHI’s ammonia combustion work in Japan and Indonesia. The deal highlights IHI’s growing role as a technology partner for decarbonizing legacy thermal power assets using ammonia co-firing and fuel conversion solutions. Now we’ll examine how this ammonia-focused retrofit...

Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s drug Leqembi, underscoring the scale of its neurology operations. This combination of strong Leqembi revenue and fresh quarterly sales data highlights how Eisai’s neuroscience focus is increasingly anchored by a single high-impact Alzheimer’s therapy. Next, we’ll examine how Leqembi’s ¥88 billion revenue contribution and the latest...

Full year 2026 results set the tone for West Japan Railway West Japan Railway (TSE:9021) has drawn fresh attention after reporting full year results to March 31, 2026, with sales of ¥1,845,840 million and net income of ¥127,499 million. Basic earnings per share from continuing operations came in at ¥277.73. Investors now have a new reference point ahead of the company’s 2026 earnings call scheduled for May 1. See our latest analysis for West Japan Railway. At a share price of ¥2,857.0, West...

As global markets navigate a complex landscape of steady interest rates, geopolitical tensions, and robust corporate earnings, investors are keenly observing the performance of major indices like the S&P 500 and Nasdaq Composite, which have shown impressive gains. In this dynamic environment, dividend stocks present an attractive option for those seeking income stability amidst market volatility; these stocks often belong to companies with strong fundamentals that can weather economic...

Why Tokyo Electron stock is in focus after fresh guidance Tokyo Electron (TSE:8035) drew investor attention after issuing earnings guidance for the first half of the fiscal year that came in above market expectations, linked to AI related demand and customer capacity expansion. See our latest analysis for Tokyo Electron. The above consensus guidance has come alongside a 1 day share price return of 6.89% and a 30 day share price return of 23.50%. The 1 year total shareholder return of 128.83%...

In April 2026, Asahi Kasei Corporation filed a new ¥200,000,000,000 bond shelf registration and withdrew its prior 2020 bond shelf, while also advancing its pharmaceutical pipeline by starting a Phase I trial in Japan for AK1940, a novel peptide-based TNF receptor 1 antagonist targeting autoimmune diseases. This combination of refreshed funding flexibility and clinical progress highlights how Asahi Kasei is aligning its balance sheet and research efforts around pharmaceuticals as a core...